Tango Therapeutics Reports Discontinuation Of TNG348 Program; Says Grade 3/4 Liver Function Abnormalities Were Observed In Patients Remaining On Study Longer Than Eight Weeks
Portfolio Pulse from Benzinga Newsdesk
Tango Therapeutics has discontinued its TNG348 program due to Grade 3/4 liver function abnormalities observed in patients after eight weeks. The program was in a phase 1/2 clinical trial for BRCA1/2-mutant and HRD+ cancers. No patients had received the combination of TNG348 and olaparib.
May 23, 2024 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Tango Therapeutics has discontinued its TNG348 program due to severe liver function abnormalities in patients. This decision impacts the company's pipeline and could affect investor confidence.
The discontinuation of the TNG348 program due to severe liver function abnormalities is a significant setback for Tango Therapeutics. This impacts their clinical pipeline and could lead to a negative reaction from investors, affecting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100